BRWA
ECYT

B. Riley Wealth Advisors’s Endocyte, Inc. Common Stock ECYT Stock Holding History

B. Riley Wealth Advisors’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,500
Closed -$9 – 2355
2014
Q4 		$9 Buy
+1,500
New +$9.14K ﹤0.01% 2945
2014
Q3 		– Sell
-1,500
Closed -$9.88K – 2195
2014
Q2 		$9.88K Buy
+1,500
New +$16.9K ﹤0.01% 1792

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

B. Riley Wealth Advisors's ECYT Position: Q1 2015 in Review

B. Riley Wealth Advisors sold out of Endocyte, Inc. Common Stock (ECYT) in Q1 2015, closing a stake of 1,500 shares — an estimated $9 sold.

B. Riley Wealth Advisors first reported a position in ECYT in Q2 2014 and held it in 2 quarters. The position peaked at $9.88K in Q2 2014. 98 funds tracked by Wall St. Rank hold ECYT as of Q1 2015.

  • B. Riley Wealth Advisors reported no remaining Endocyte, Inc. Common Stock position as of Q1 2015 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 1,500 Endocyte, Inc. Common Stock shares in Q1 2015, an estimated $9.
  • B. Riley Wealth Advisors first reported a position in Endocyte, Inc. Common Stock in Q2 2014 and held it in 2 quarters.
  • B. Riley Wealth Advisors's Endocyte, Inc. Common Stock position peaked at $9.88K in Q2 2014.
  • 98 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q1 2015.

Based on B. Riley Wealth Advisors's 13F filing for Q1 2015, filed 14 May 2015.